Remove healthcare-authority policy-compliance
article thumbnail

Agents Vs. Agentic AI: What In-House Counsel Need To Know About These 2 AI Frontiers

Above The Law

While both terms describe AI applications, their distinctions are critical when crafting governance, compliance, and liability strategies. Why The Distinction Matters For in-house lawyers, distinguishing between these AI types is not just semantics — it informs how you assess risks, ensure regulatory compliance, and allocate liability.

Legal 119
article thumbnail

Australia Human Rights Commission expresses concerns over conditions in immigration detention facility

JURIST

The report highlights issues related to drug trafficking, insufficient healthcare services and the overall well-being of detainees and staff members. Furthermore, the report draws attention to the inadequate provision of healthcare services within the detention centre.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Catastrophic Breach Of A Law Firm And A County Office

Above The Law

However, according to the notice, certain information provided by healthcare organizations to which Bassford Remele provides legal services may have been accessed, including Social Security numbers and medical record information. Enable Conditional Access Policy for account logins with Microsoft 365.

Law Firms 113
article thumbnail

Generative AI Versus Agentic AI: Navigating The AI Frontier For In-House Counsel

Above The Law

But its autonomy introduces higher stakes for liability and compliance. These distinctions drive everything from how you structure contracts with AI vendors to how you approach regulatory compliance and governance. Now consider Agentic AI in healthcare. Whos responsible when Agentic AI makes a mistake? Then theres privacy.

article thumbnail

Hyman, Phelps & McNamara Enters its 45th Year Continuing to Expand its Capabilities to Meet Client Needs

FDA Law Blog

In her distinguished FDA career, Dr. Lowy provided thought leadership in drug policy and product development for rare endocrinologic diseases, opioids, sarcopenia, and cancer cachexia. Andrew Hull brings his expertise to the firms enforcement, compliance, and litigation practice. Director Karla L. Palmer, commented.

article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law Blog

Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). Lenz, Principal Medical Device Regulation Expert & Sophia R. Gaulkin & Jeffrey N.

article thumbnail

HP&M is Pleased to Welcome Lisa Baumhardt (Senior Medical Device Regulation Expert) and Sophia Gaulkin (Associate) to the Firm

FDA Law Blog

Baumhardt develops regulatory strategies, prepares pre-submissions and regulatory market authorization submissions, drafts regulatory policies and procedures, and reviews advertising and promotional materials. Baumhardt advises clients on complaint handling, MDRs, Quality System Regulation compliance and enforcement matters.